DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Congestive Heart Failure

Intervention: Candesartan (Drug); Placebo (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Dr Salim Yusuf, Principal Investigator

Summary

A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function

Clinical Details

Official title: Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Cardiovascular mortality or hospitalisation due to congestive heart failure

Secondary outcome: Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female aged 18 or above

- Congestive Heart Failure with symptoms for more than 4 weeks before starting study

- Provision of informed consent

Exclusion Criteria:

- Current low blood pressure with symptoms

- Liver disease considered significant by the study doctor

- Pregnant or lactating females

Locations and Contacts

Additional Information

Starting date: June 1999
Last updated: January 24, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017